nach oben

Wiener klinische Wochenschrift

Erschienen in:

18.11.2019 | original article

Assessing the health-related quality of life in type 2 diabetes patients treated with insulin and oral antidiabetic agents

verfasst von: Nawras Al-Taie, Delia Maftei, Alexandra Kautzky-Willer, Michael Krebs, Harald Stingl

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 5-6/2021

Einloggen, um Zugang zu erhalten

Summary

Background

Assessing the quality of life (QOL) for patients with type 2 diabetes is an essential part of diabetes management, especially for the evaluation of new antidiabetic treatments and glucose monitoring technologies. Accordingly, the aim of this study was to assess QOL according to treatment types.

Methods

This cross-sectional study included 170 patients with type 2 diabetes from the region of Melk in Lower Austria. Of the patients 61 used only oral antidiabetic agents (OAD) and 109 patients were treated with insulin (with or without OAD). The QOL was assessed in patients using sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors). Among the 170 patients with type 2 diabetes 95 used SGLT2 inhibitors. The World Health Organization Quality of Life BREF (WHOQOL-BREF) assessment was used to assess QOL among these patients. The Mann–Whitney U-test was utilized in this study and a P value <0.05 was considered statistically significant.

Results

Regarding the 170 participants, most were male (58.82%) and the mean glycated hemoglobin (HbA1c) level was 55.46 ± 12.30 mmol/mol (7.2%). The WHOQOL-BREF scores among type 2 diabetes patients were relatively high, which reflect a good QOL and the mean physical, psychological, social and environmental domain scores were 64.53 ± 20.15, 71.29 ± 18.08, 70.10 ± 20.08, and 84.419 ± 11.22 SD, respectively. There were no statistically significant differences in WHOQOL scores of the domains between the insulin-treated group and OAD group and between the group treated with SGLT2 inhibitors and the group not treated with SGLT2 inhibitors.

Conclusion

This study showed no QOL distinctions between treatment groups in patients with type 2 diabetes; however, a large cohort study is needed to examine these groups further.

Nächster Artikel Impact of sense of coherence on quality of life in patients with multiple sclerosis

World Health Organization. (2018) Global report on diabetes. WHO Diabetes. https://www.who.int/news-room/fact-sheets/detail/diabetes.

Association AD. Economic costs of diabetes in the U.S. 2017. Diabetes Care. 2018; https://doi.org/10.2337/dci18-0007.CrossRef

Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycaemia in type 2 diabetes. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;61:2461–98. https://doi.org/10.2337/dci18-0033.CrossRef

World Health Organization. Division of mental health and prevention of substance abuse. WHOQOL and spirituality, religiousness and personal beliefs (SRPB) WHO. 1998. https://apps.who.int/iris/bitstream/handle/10665/70897/WHO_MSA_MHP_98.2_eng.pdf?sequence=1.

Silva PA, Soares SM, Santos JF, Silva LB. Ponto de corte para o WHOQOL-bref como preditor de qualidade de vida de idosos. Rev Saude Publica. 2014;48:390–7. https://doi.org/10.1590/S0034-8910.2014048004912.CrossRefPubMedPubMedCentral

Neuhäuser M. Wilcoxon–Mann–whitney test. In: Lovric M, editor. Int Enc of Stat Sci. Berlin, Heidelberg: Springer; 2011. pp. 1656–8. https://doi.org/10.1007/978-3-642-04898-2_615.CrossRef

Chambers JM, Cleveland WS, Kleiner B, and Tukey PA. (1983). Comparing Data Distributions. In Graphical Methods for Data Analysis, 62. Belmont, California: Wadsworth International Group.

Fal AM, Jankowska B, Uchmanowicz I, Sen M, Panaszek B, Polanski J. Type 2 diabetes quality of life patients treated with insulin and oral hypoglycemic medication. Acta Diabetol. 2011;48:237–42. https://doi.org/10.1007/s00592-010-0244-y.CrossRefPubMed

Raghavendra N, Viveki R, Gadgade A. An observational study to assess the health-related quality of life of type 2 diabetes mellitus patients attending a tertiary care hospital, Belagavi. Int J Commun Med Pub Health. 2017;4:3347–53. https://doi.org/10.18203/2394-6040.ijcmph20173843.CrossRef

10.

Gholami A, Azini M, Borji A, Shirazi F, Sharafi Z, Zarei E. Quality of life in patients with type 2 diabetes: application of WHOQOL-BREF scale. Shiraz E Med J. 2013;14:162–71. http://emedicalj.com/en/articles/20394.html..

11.

Chaveepojnkamjorn W, Pichainarong N, Schelp FP, Mahaweerawat U. Quality of life and compliance among type 2 diabetic patients. Southeast Asian J Trop Med Public Health. 2008;39:328–34.PubMed

12.

Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6‑year study. Diabetes Res Clin Pract. 1995;28:103–17. https://doi.org/10.1016/0168-8227(95)01064-K.CrossRefPubMed

13.

Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89. https://doi.org/10.1056/NEJMoa0806470.CrossRefPubMed

14.

Pouwer F, Hermanns N. Insulin therapy and quality of life. A review. Diabetes Metab Res Rev. 2009;25:S4–S10. https://doi.org/10.1002/dmrr.981.CrossRefPubMed

15.

Association AD. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). UK Prospective Diabetes Study Group. Diabetes Care. 1999;22:1125–36. https://doi.org/10.2337/diacare.22.7.1125.CrossRef

16.

Shah S, Zilov A, Malek R, Soewondo P, Bech O, Litwak L. Improvements in quality of life associated with insulin analogue therapies in people with type 2 diabetes: results from the A1chieve observational study. Diabetes Res Clin Pract. 2011;94(3):364–70. https://doi.org/10.1016/j.diabres.2011.10.020.CrossRefPubMed

17.

Pufal J, Gierach M, Pufal M, Bronisz A, Kiełbasa L, Junik R. The influence of socio-demographic and clinical factors on quality of life of patients with type 2 diabetes. Diabetol Kliniczna. 2004;4:137–136. kpbc.ukw.edu.pl/content/44867/020408pufal.pdf [in Polish].

18.

Vijan S, Hayward RA, Ronis DL, Hofer TP. Brief report: the burden of diabetes therapy: implications for the design of effective patient-centered treatment regimens. J Gen Intern Med. 2005;20:479–82. https://doi.org/10.1111/j.1525-1497.2005.0117.x.CrossRefPubMedPubMedCentral

19.

Dąbrowski M, Filip W, Huc B. Association between insulin therapy and quality of life in diabetes. J Pre Clin Clin Res. 2017;11:10–4. https://doi.org/10.26444/jpccr/75145.CrossRef

20.

Grandy S, Langkilde AM, Sugg JE, Parikh S, Sjöström CD. Health-related quality of life (EQ-5D) among type 2 diabetes mellitus patients treated with dapagliflozin over 2 years. Int J Clin Pract. 2014;68:486–94. https://doi.org/10.1111/ijcp.12341.CrossRefPubMed

21.

Traina S, Guthrie R, Slee A. The impact of weight loss on weight-related quality of life and health satisfaction: results from a trial comparing canagliflozin with sitagliptin in triple therapy among people with type 2 diabetes. Postgrad Med. 2014;126:7–15. https://doi.org/10.3810/pgm.2014.05.2752.CrossRefPubMed

Titel: Assessing the health-related quality of life in type 2 diabetes patients treated with insulin and oral antidiabetic agents
verfasst von: Nawras Al-Taie
Delia Maftei
Alexandra Kautzky-Willer
Michael Krebs
Harald Stingl
Publikationsdatum: 18.11.2019
Verlag: Springer Vienna
Erschienen in: Wiener klinische Wochenschrift / Ausgabe 5-6/2021
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI: https://doi.org/10.1007/s00508-019-01573-0

Veranstaltungstipps:

mitteilungen der gesellschaft der ärzte in wien

Plateletcrit may not provide a distinction between patients with adult-onset Still’s disease and sepsis

letter to the editors

Emergency department overcrowding

review article

Treatment of partial thickness burns of the face with Acticoat7™

Open Access
original article

Prevalence of neuropathy in patients with type 2 diabetes in Iran

review article

Diagnosis of hepatic nuclear factor 1A monogenic diabetes mellitus (HNF1A-MODY) impacts antihyperglycemic treatment

short report

Springer Medizin Österreich

Assessing the health-related quality of life in type 2 diabetes patients treated with insulin and oral antidiabetic agents

Summary

Background

Methods

Results

Conclusion

Weitere Artikel der Ausgabe 5-6/2021

Veranstaltungstipps:

Plateletcrit may not provide a distinction between patients with adult-onset Still’s disease and sepsis

Emergency department overcrowding

Treatment of partial thickness burns of the face with Acticoat7™

Prevalence of neuropathy in patients with type 2 diabetes in Iran

Diagnosis of hepatic nuclear factor 1A monogenic diabetes mellitus (HNF1A-MODY) impacts antihyperglycemic treatment

Springer Medizin Österreich

Summary

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Veranstaltungstipps:

Plateletcrit may not provide a distinction between patients with adult-onset Still’s disease and sepsis

Emergency department overcrowding

Treatment of partial thickness burns of the face with Acticoat7™

Prevalence of neuropathy in patients with type 2 diabetes in Iran

Diagnosis of hepatic nuclear factor 1A monogenic diabetes mellitus (HNF1A-MODY) impacts antihyperglycemic treatment